NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Contact the NSABP   Pathology Section   Future Meetings   NSABP Newsletters   Media Info on cMYC Study   Media Info on STAR   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-36   Protocol B-37   Protocol B-39   Protocol B-40   Protocol B-41   Protocol B-42   Protocol C-10   Protocol R-04 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR   BreastCancerPrevention.com Bibliography of Publications Related Web Sites About the NSABP Web Site Helper Applications Links to Major Search Engines Medical Search Engines To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview Protocol B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response Specific Aims The primary aims of this study are to determine whether the regimen of AC → weekly paclitaxel (WP) plus trastuzumab plus lapatinib yields a greater rate of pCR than the regimen of AC → WP plus trastuzumab and to determine whether the regimen of AC → WP plus lapatinib yields a greater rate of pCR than the regimen of AC → WP plus trastuzumab.